Wednesday, April 1, 2015
Welcome! Login in to your account Forgot your password? Recover your password
Asthma people may soon be getting a non-inhaling drug treatment. GlaxoSmithKline (GSK) has announced they have passed through the test in two phase III studies in patients suffering with eosinopilic asthma. Researchers found the new drug mepolizumab reduces number of exacerbations and has also significantly cut down the daily oral corticosteroid use.
Mepolizumab drug is an IL-5 antagonist monoclonal antibody. If it is approved, it would be the first of its kind used in the treatment of severe asthma.
GSK Respiratory Therapy Area Unit Head Dave Allen said in a press release they have two studies that resulted with exacerbations reduction in a specific group of patients suffering from severe asthma and they continue to exacerbate despite the high doses treatment of their current maintenance therapies.
The researchers studied about 600 patients who were randomized to get either 100 mg of the drug as a subcutaneous injection, 75 mg of it in IV form, or a placebo every 4 weeks for 32 weeks. All were also allowed to take their regular maintenance therapy for the disease.
At the end of the study period those group who were treated with IV form experienced a 47 percent reduction in exacerbations and those who received it subcutaneously showed 53 percent reduction compared to those who were treated with placebo.
Talking about the adverse events the researchers say it was found by 83 percent in the IV group, 78 percent in injection group and 84 percent in the third group.
It was also found serious events occurred 7 percent in the IV group, 8 percent in injection group and 14 percent in the placebo group.